直肠癌患者放射治疗前后IL-17和IL-23的表达及意义

doi:10.19739/j.cnki.issn1001-9510.2021.03.007

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (764 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the level of IL-17 and IL-23 in peripheral blood of patients with rectal cancer to analyze their association with clinicopathological characteristics and prognosis before and after radiotherapy.Methods Blood samples were collected from 24 patients with rectal cancer before and after radiotherapy, and the levels of IL-17 and IL-23 in peripheral blood of the patients were detected by ELISA. All patients received 50Gy radiotherapy after surgery.Results Protein expression level of IL-17 was correlated with tumor differentiation and lymph node metastasis in rectal cancer patients (P<0.05), whereas serum IL-23 level showed correlated only with lymph node metastasis (P<0.05). Significant differences were observed between serum IL-17 and IL-23 levels in rectal cancer patients before and after radiotherapy (P<0.05). Serum levels of IL-17 and IL-23 can be used to effectively diagnose tumor differentiation and lymph node metastasis of rectal cancer patients. Multivariate Cox proportional hazards regression analysis showed that the expression of IL-23 may be independent risk factor for poor prognosis (P<0.05).Conclusion The concentration of IL-17 and IL-23 obviously increased in peripheral blood of patients with rectal cancer, both of them were correlated with radiotherapy. Detection of IL-17 and IL-23 levels has certain clinical significance in the diagnosis and prognosis of rectal cancer patients.

Key words： rectal cancer radiotherapy IL-17 IL-23 prognosis

Received: 23 September 2020

PACS:

R735.3+7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIAN Jinbo
	LIU Peng
	ZHANG Luyan
	NI Na
	WANG Xiaole
	NING Fangling

Cite this article:

JIAN Jinbo,LIU Peng,ZHANG Luyan, et al. Expression of IL-17 and IL-23 and significance in rectal cancer patients before and after radiotherapy[J]. 滨州医学院学报, 2021, 44(3): 192-195.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2021.03.007 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2021/V44/I3/192

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[2] SCHAEYBROECK S V, ALLEN W L, TURKINGTON R C, et al. Implementing prognostic and predictive biomarkers in CRC clinical trials [J]. Nat Rev Clin Onco, 2011,8(4):222-232.
[3] QIAN X, CHEN H, WU X, et al. Interleukin-17 Acts as double-edged sword in anti-tumor immunity and tumorigenesis[J]. Cytokine, 2017, 89:34-44.
[4] BOUTET M A, NERVIANI A, GALLO AFFLITTO G, et al. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints [J]. Int J Mol Sci, 2018, 19(2):530.
[5] GRIVENNIKOV S I, WANG K, MUCIDA D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth[J]. Nature, 2012, 491(7423): 254-258.
[6] WANG K, KARIN M. The IL-23 to IL-17 cascade inflammation-related cancers[J]. Clin Exp Rheumatol, 2015, 33(4 suppl 92): S87-S90.
[7] GRIVENNIKOV S, KARIN E, TERZIC J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer [J]. Cancer cell,2009, 15(2):103-113.
[8] SICA A, ALLAVENA P, MANTOVANI A. Cancer related inflammation: The macrophage connection[J]. Cancer Lett, 2008, 267(2): 204-215.
[9] LEE Y, KIM S J, CHOO J, et al. miR-23a-3p is a Key Regulator of IL-17C-Induced Tumor Angiogenesis in Colorectal Cancer [J]. Cells, 2020, 9(6):1363.
[10] SONG X, GAO H, LIN Y, et al. Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis[J]. Immunity, 2014, 40(1): 140-152.
[11] PUNT S, FLEUREN G J, KRITIKOU E, et al. Angels and demons: Th17 cells represent a beneficial response, while neutrophil IL-17 is associated with poor prognosis in squamous cervical cancer[J]. Oncoimmunology, 2015, 4(1): e984539.
[12] JIN C, LAGOUDAS G K, ZHAO C, et al. Commensal Microbiota Promote Lung Cancer Development via γδ T Cells [J]. Cell, 2019, 176(5):998-1013.e16.
[13] CHEN X, CAI G, LIU C, et al. IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1⁺ stem cells[J]. J Exp Med, 2019, 216(1): 195-214.
[14] BEHZADI P, BEHZADI E, RANJBAR R. IL-12 Family Cytokines: General Characteristics, Pathogenic Microorganisms, Receptors, and Signalling Pathways [J].Acta Microbiol Immunol Hung, 2016, 63(1):1-25.
[15] 李原. IL-23R表达型细胞在结直肠癌中的作用及结直肠癌同时性肝转移外科治疗策略探讨[D].北京:北京协和医学院,2016.
[16] COCCO C, CANALE S, FRASSON C, et al. Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells [J]. Blood, 2010, 116(19):3887-3898.
[17] LAN F, ZHANG L, WU J C, et al. IL-23/IL-23R: Potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma[J]. Int J Color Dis, 2011, 26(12): 1511-1518.
[18] CHEN G, LIANG Y, GUAN X, et al. Circulating low IL-23:IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer[J]. Am J Transl Res, 2016, 8(5): 2255-2264.
[19] HU W H, CHEN H H, YEN S L, et al. Increased expression of interleukin-23 associated with progression of colorectal cancer[J]. J Surg Oncol, 2017, 115(2): 208-212.
[20] PARK Y J, KUEN D S, CHUNG Y. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance [J]. Exp Mol Med, 2018, 50(8):109.
[21] SUI G, QIU Y, YU H, et al. Interleukin-17 promotes the development of cisplatin resistance in colorectal cancer[J]. Oncol Lett, 2019, 17(1): 944-950.
[22] 黄伟刚,陈荣策,项嘉亮,等.结直肠癌患者血清中IL-17和IL-6的表达及其临床意义[J].肿瘤,2012,32(6):458-461.
[23] ZHONG W J, LI Q S. Rituximab or irradiation promotes IL-17 secretion and thereby induces resistance to rituximab or irradiation[J]. Cell Mol Immunol, 2017, 14(12): 1020-1022.